Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.32

+0.7%

Nov 5 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (238)	3/31/1999 2:09:00 PM
From: RCMac	of 1475

DAK, PB, Some context re competition between anti-CD2 and anti-CD-40L agents: Message 7995634 "Not only is BGEN committed to more clinicals for anti-CD40L than MEDI is for 507, they're already thinking ahead for meeting the huge demand. Again I ask..... is it time for MEDI to sublicense 507 for indications that they just can't bite off?????? We could win all the battles and lose the war." Message 6574843 (and replies) Message 6533299 See also: Message 7324662 Also, BTRN's 10-K is out today. --RCM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next